Chenel Capital

KalGene Pharmaceuticals

Industry
Healthcare
Headquarters
Canada
Description

KalGene has developed an anti-amyloid therapy to slow the progression of Alzheimer’s disease that overcomes the safety issues inherent with antibody-based approaches, including Biogen’s Aducanumab, is more effective and requires less product for efficacy.

KG207 is a bi-specific fusion protein that targets the neurotoxic amyloid- β42 oligomeric peptides that are thought to be neurotoxic and are precursors to abundant amyloid plaques seen in the brains of Alzheimer’s patients.

Senior Management
Anthony J. Giovinazzo, MBAAnthony J. Giovinazzo, MBA

Chairman

Nickolay V Kukekov, PhDNickolay V Kukekov, PhD

CEO